drugset / Trial / NCT00526409
LAL-AR-N-2005:Study Treatment for Children High Risk Acute Lymphoblastic Leukemia
Non-randomizedSingle-groupOpen-labelTreatment
Summary
The study objective is to improve the global results obtained with LAL-AR-93 study, reaching an event free survival between 60-70%. Identify patients with bad prognosis, with minimal residual disease,who can benefit of allogenic bone marrow transplantation
Timeline
- Start
- 2005-06
- Primary completion
- 2014-10
- Completion
- 2014-10
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Cyclophosphamide | Other / unclassified | — | Intravenous |
| Subject | Cytarabine | Small molecule | — | Intravenous |
| Subject | Daunorubicin | Small molecule | — | Intravenous |
| Subject | Methotrexate | Small molecule | 20 mg/m2 | Intramuscular |
| Subject | Prednisolone | Other / unclassified | — | Oral |
| Subject | Vincristine | Small molecule | 1.5 mg/m2 | Intravenous |
| Subject | asparaginase | Protein / enzyme biologic | 20000 unknown | Intramuscular |